Veradermics, Inc
MANE NYSE Pharmaceutical Preparations Financials FY2024–FY2025
Last close · Oct 23, 2026
$138.78
0.2%What Veradermics, Inc does
No business description yet.
- Legal name
- Veradermics, Inc
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Accession · CIK
- 0001827635-26-000013
0001827635
Revenue and margins
Veradermics, Inc had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$71.6M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Veradermics, Inc returned — to shareholders in fiscal 2025. The diluted share count rose 1.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably Veradermics, Inc can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $53.1M | $142M |
| Interest coverage | −45.8x | — |
| Current ratio | 11.8x | 16.7x |
| Quick ratio | 11.8x | 16.7x |
| Total assets | $55.5M | $153M |
| Total liabilities | $4.7M | $9.2M |
| Shareholders' equity | −$48.5M | −$121M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✓ | ✕ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — / 3 | — / 6 |
| Accruals ratio | −5.0% | 1.5% |
| Altman Z'' | −10.92 | −13.54 |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Research and development | $23.3M | $62.1M |
| Operating income | −$26.8M | −$72.3M |
| Interest expense | $0.6M | $0.0M |
| Pretax income | −$26.5M | −$70.0M |
| Income tax | $0.0M | $0.0M |
| Net income | −$26.5M | −$70.0M |
| Net income to common | −$27.3M | −$83.4M |
| Diluted EPS | −$37.05 | −$111.91 |
| Diluted shares | 0.00B | 0.00B |
| Cash flow | ||
| Cash from operations | −$23.7M | −$71.6M |
| Capital expenditure | $0.0M | $0.0M |
| Free cash flow | −$23.7M | −$71.6M |
| Stock-based compensation | $0.3M | $1.4M |
| Balance sheet | ||
| Cash and short-term investments | $53.1M | $142M |
| Current assets | $55.5M | $152M |
| Current liabilities | $4.7M | $9.2M |
| Property and equipment, net | $0.0M | $0.0M |
| Total assets | $55.5M | $153M |
| Total liabilities | $4.7M | $9.2M |
| Preferred stock | — | $0.0M |
| Shareholders' equity | −$48.5M | −$121M |
| Returns | ||
| Return on capital employed | −52.7% | −50.4% |
| Return on assets | −47.7% | −67.3% |
| Growth | ||
| Share count change | — | 1.1% |
| Financial health | ||
| Interest coverage | −45.8x | — |
| Current ratio | 11.8x | 16.7x |
| Quick ratio | 11.8x | 16.7x |
| Quality scores | ||
| Altman Z'' | −10.9 | −13.5 |
| Accruals ratio | −5.0% | 1.5% |
Source: SEC EDGAR XBRL filings (CIK 0001827635). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.